Metabolic Bone Disease in Primary Biliary Cirrhosis

被引:22
作者
Glass, Lisa M. [1 ]
Su, Grace Li-Chun [2 ]
机构
[1] Univ Michigan Hlth Syst, VA Ann Arbor Hlth Care Syst, Dept Internal Med, Gastroenterol Sect, 2215 Fuller Rd, Ann Arbor, MI 48105 USA
[2] Univ Michigan, Sch Med, Gastroenterol Sect, Specialty Care & Access,VA Ann Arbor Hlth Care Sy, 2215 Fuller Rd, Ann Arbor, MI 48105 USA
关键词
Primary biliary cirrhosis; Metabolic bone disease; Osteoporosis; Antiresorptive agents; CHOLESTATIC LIVER-DISEASE; URSODEOXYCHOLIC ACID; BIOCHEMICAL RESPONSE; CONTROLLED-TRIAL; MINERAL DENSITY; VITAMIN-K; OSTEOPOROSIS; ALENDRONATE; THERAPY; OSTEODYSTROPHY;
D O I
10.1016/j.gtc.2016.02.009
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Primary biliary cirrhosis (PBC) is a liver-specific autoimmune disease that primarily affects women (female-to-male ratio, 10:1) between 40 and 60 years of age. Metabolic bone disease is a common complication of PBC, affecting 14% to 52% of patients, depending on the duration and severity of liver disease. The osteoporosis seen in PBC seems mainly due to low bone formation, although increased bone resorption may contribute. Treatment of osteoporosis consists primarily of antiresorptive agents. Additional large prospective, long-term studies in patients with PBC are needed to determine efficacy in improving bone density as well as reducing fracture risk.
引用
收藏
页码:333 / +
页数:12
相关论文
共 47 条
  • [41] URSODIOL FOR THE LONG-TERM TREATMENT OF PRIMARY BILIARY-CIRRHOSIS
    POUPON, RE
    POUPON, R
    BALKAU, B
    HUET, PM
    WILLEMS, B
    MATHIEUCHANDELIER, C
    PARIS, JC
    MATHIEXFORTUNET, H
    CAPRON, JP
    CAPRON, D
    DHUMEAUX, D
    METREAU, JM
    DEUGNIER, Y
    OPOLON, P
    BOUSQUET, O
    PAYEN, JL
    BRESSONHADNI, S
    MIGUET, JP
    DEGOS, F
    BEAUGRAND, M
    TRINCHET, JC
    BLANC, F
    CASSAN, P
    GINESTON, JL
    MORIN, T
    PARELON, G
    MICHEL, H
    ETIENNE, JP
    BUFFET, C
    COUZIGOU, P
    LEVYBRUHL, A
    PARIENTE, EA
    VALLA, A
    VERWAERDE, JC
    CHAPUT, JC
    POYNARD, T
    GAUTHIER, A
    LEVY, VG
    PAUMGARTNER, G
    NIARD, AM
    ESCHWEGE, E
    ATLAN, P
    ATTALI, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (19) : 1342 - 1347
  • [42] Bisphosphonates for osteoporosis in primary biliary cirrhosis
    Rudic, Jelena S.
    Giljaca, Vanja
    Krstic, Miodrag N.
    Bjelakovic, Goran
    Gluud, Christian
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):
  • [43] Lithocholic acid downregulates vitamin D effects in human osteoblasts
    Ruiz-Gaspa, S.
    Guanabens, N.
    Enjuanes, A.
    Peris, P.
    Martinez-Ferrer, A.
    Martinez de Osaba, M. J.
    Gonzalez, B.
    Alvarez, L.
    Monegal, A.
    Combalia, A.
    Pares, A.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2010, 40 (01) : 25 - 34
  • [44] Calcitriol for bone loss in patients with primary biliary cirrhosis
    Shiomi, S
    Masaki, K
    Habu, D
    Takeda, T
    Nishiguchi, S
    Kuroki, T
    Ochi, H
    [J]. JOURNAL OF GASTROENTEROLOGY, 1999, 34 (02) : 241 - 245
  • [45] Calcitriol for bone disease in patients with cirrhosis of the liver
    Shiomi, S
    Masaki, K
    Habu, D
    Takeda, T
    Nishiguchi, S
    Kuroki, T
    Tanaka, T
    Ochi, H
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 14 (06) : 547 - 552
  • [46] Fracture risk in people with primary biliary cirrhosis: A population-based cohort study
    Solaymani-Dodaran, Masoud
    Card, Tim R.
    Aithal, Guruprasad P.
    West, Joe
    [J]. GASTROENTEROLOGY, 2006, 131 (06) : 1752 - 1757
  • [47] Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebo-controlled trial
    Zein, CO
    Jorgensen, RA
    Clarke, B
    Wenger, DE
    Keach, JC
    Angulo, P
    Lindor, KD
    [J]. HEPATOLOGY, 2005, 42 (04) : 762 - 771